Indaptus Therapeutics, Inc. (INDP) Research

Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.

Market snapshot

Symbol
INDP
Price
$3.90
Day change
-13.33%
Market cap
$6.8M
P/E ratio
-0.45x
52-week range
0.92-19.908
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Avenue Therapeutics, Inc. (ATXI)
  • Azitra, Inc. (AZTR)
  • GT Biopharma, Inc. (GTBP)
  • Lipella Pharmaceuticals Inc. (LIPO)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Psyence Biomedical Ltd. (PBM)
  • Protagenic Therapeutics, Inc. (PTIX)
  • Revelation Biosciences, Inc. (REVB)

Recent insider activity

  • Lu Qinglai — trade (0 shares) on 2026-04-08
  • Yao Yun — trade (0 shares) on 2026-03-23
  • SINO LION VENTURES Ltd — trade (0 shares) on 2026-03-23
  • Dai Junyi — trade (0 shares) on 2026-03-23
  • Lazar David E. — S-Sale (196800 shares) on 2026-03-23

Open Indaptus Therapeutics, Inc. (INDP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.